Legato Capital Management’s Cytokinetics CYTK Stock Holding History

Legato Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.24M	Buy	26,239 +14,905	+132%	+$1.07M	0.19%	170
2026 Q1	$747K	Sell	11,334 -20,614	-65%	-$1.31M	0.07%	381
2025 Q4	$2.03M	Buy	31,948 +14,345	+81%	+$892K	0.17%	187
2025 Q3	$967K	Buy	+17,603	New	+$725K	0.11%	298
2024 Q3	–	Sell	-4,380	Closed	-$237K	–	585
2024 Q2	$237K	Buy	+4,380	New	+$264K	0.03%	511
2024 Q1	–	Sell	-15,636	Closed	-$1.31M	–	577
2023 Q4	$1.31M	Buy	+15,636	New	+$566K	0.17%	192
2023 Q2	–	Sell	-14,038	Closed	-$494K	–	588
2023 Q1	$494K	Sell	14,038 -2,897	-17%	-$118K	0.09%	360
2022 Q4	$776K	Buy	+16,935	New	+$729K	0.15%	240

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Legato Capital Management's CYTK Position: Q2 2026 in Review

Legato Capital Management increased its Cytokinetics (CYTK) stake by 132% in Q2 2026, buying an estimated $1.07M and bringing the position to 26,239 shares worth $2.24M. The position accounts for 0.19% of the portfolio, ranked #170.

Legato Capital Management first reported a position in CYTK in Q4 2022 and has held it in 8 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

Legato Capital Management held 26,239 shares of Cytokinetics worth $2.24M as of Q2 2026.
Legato Capital Management bought 14,905 Cytokinetics shares in Q2 2026, an estimated $1.07M.
Cytokinetics made up 0.19% of Legato Capital Management's portfolio in Q2 2026, its #170 holding.
Legato Capital Management first reported a position in Cytokinetics in Q4 2022 and has held it in 8 quarters since.
482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Legato Capital Management's 13F filing for Q2 2026, filed 6 Aug 2026.